605 NHS-IL12 plus Entinostat combination effectively targets anti-PD-1/PD-L1 checkpoint resistant murine tumors harboring MHC Class I and antigen processing machinery deficiency

• Jeffrey Schlom,
• Sofia Gameiro,
• Christine Minnar,
• Paul Chariou,
• Kristin Hicks

Affiliations

Jeffrey Schlom

Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA

Sofia Gameiro

Aff1 NCI/CCR/LTIB Bethesda MD USA

Christine Minnar

National Cancer Institute, Bethesda, MD, USA

Paul Chariou

National Cancer Institute, Bethesda, MD, USA

Kristin Hicks

National Cancer Institute, Bethesda, MD, USA